about
Multiple Sclerosis in Pediatrics: Current Concepts and Treatment OptionsInfection risk in patients on multiple sclerosis therapeutics.The effectiveness of dimethyl fumarate monotherapy in the treatment of relapsing-remitting multiple sclerosis: a systematic review and meta-analysis.Antibody blockade of CLEC12A delays EAE onset and attenuates disease severity by impairing myeloid cell CNS infiltration and restoring positive immunity.Defining a role for laquinimod in multiple sclerosis.A 2-year observational study of patients with relapsing-remitting multiple sclerosis converting to glatiramer acetate from other disease-modifying therapies: the COPTIMIZE trial.The role of immune cells, glia and neurons in white and gray matter pathology in multiple sclerosis.Exogenous IFN-beta regulates the RANKL-c-Fos-IFN-beta signaling pathway in the collagen antibody-induced arthritis model.Compliance to fingolimod and other disease modifying treatments in multiple sclerosis patients, a retrospective cohort study.Anti-CCP antibody levels are not associated with MS: results from a case-control study.Multiple sclerosis prevalence in the United States commercially insured population.Kappa opioid receptor activation alleviates experimental autoimmune encephalomyelitis and promotes oligodendrocyte-mediated remyelination.Cytometric profiling in various clinical forms of multiple sclerosis with respect to CD21+, CD32+, and CD35+ B and T cells.Teriflunomide in relapsing multiple sclerosis: therapeutic utilityMultiple Sclerosis: Pathogenesis, Symptoms, Diagnoses and Cell-Based Therapy.Blood Concentrations of Cadmium and Lead in Multiple Sclerosis Patients from Iran.Plant Derived Phytocompound, Embelin in CNS Disorders: A Systematic Review.Ischemic colitis with type I interferons used in the treatment of hepatitis C and multiple sclerosis: an evaluation from the food and drug administration adverse event reporting system and review of the literature.The benefits and detriments of macrophages/microglia in models of multiple sclerosisMultiple sclerosis: basic knowledge and new insights in perioperative management.Neurotrophic factors and their effects in the treatment of multiple sclerosis.Extra virgin olive oil: a key functional food for prevention of immune-inflammatory diseases.Long-term adherence of patients with relapsing-remitting multiple sclerosis to subcutaneous self-injections of interferon β-1a using an electronic device: the RIVER study.Repeated sugammadex usage in a patient with multiple sclerosis: a case report.Disease-activity-free status in patients with relapsing-remitting multiple sclerosis treated with daclizumab high-yield process in the SELECT study.Cytokine Signaling in Multiple Sclerosis and Its Therapeutic Applications.Mortality and cause of death in multiple sclerosis: findings from a prospective population-based cohort in Bizkaia, Basque Country, Spain.Co-Transplantation of Human Neurotrophic Factor Secreting Cells and Adipose-Derived Stem Cells in Rat Model of Multiple Sclerosis.Synthesis and Functional Investigations of Computer Designed Novel Cladribine-Like Compounds for the Treatment of Multiple Sclerosis.Pharmacological and non-pharmacological therapies of cognitive impairment in multiple sclerosis.Burden of disease in multiple sclerosis patients with spasticity in Germany: mobility improvement study (Move I).Systematic literature review and network meta-analysis of cladribine tablets versus alternative disease-modifying treatments for relapsing-remitting multiple sclerosis.Alemtuzumab and chronic plaque psoriasis.Differential microRNA expression in blood in multiple sclerosis.ZSTK474, a novel PI3K inhibitor, modulates human CD14+ monocyte-derived dendritic cell functions and suppresses experimental autoimmune encephalomyelitis.Embelin suppresses dendritic cell functions and limits autoimmune encephalomyelitis through the TGF-β/β-catenin and STAT3 signaling pathways.The Evaluation of Astaxanthin Effects on Differentiation of Human Adipose Derived Stem Cells into Oligodendrocyte Precursor Cells.Aldosterone exerts anti-inflammatory effects on LPS stimulated microgliaRegulation of Lymphatic GM-CSF Expression by the E3 Ubiquitin Ligase Cbl-bRegulatory B and T lymphocytes in multiple sclerosis: friends or foes?
P2860
Q28067298-3DBB3350-3BD9-4D27-B537-BFE919CC1A62Q30908652-E65360F2-1167-4A82-97A9-2876D10CC61EQ33621682-221ED117-1118-4B09-BCAF-69DA54949427Q33758969-35BB37BD-C2DA-4655-B651-8FC43CB30A31Q33847350-787D5FA3-7639-4B9F-99CB-BA1F28EAE4A3Q34459729-F61341A1-4194-4F25-933E-59BE1AD064A6Q34468304-E44CD23C-744F-4967-8919-4AF3BC0DDF9CQ34751981-D604CFE7-1AB0-4B84-A8B3-CB3BA7A84876Q35007948-112A1614-9652-4413-85ED-8CBD44338750Q35097389-2217DFF6-853D-4CD9-89F9-77D1787A1D2FQ36706025-02ECE065-1446-4A21-8ACD-DCF9EDC62EA1Q36768701-88A49049-8C52-42A0-B172-3FBC73BBB107Q36996819-0B566C3A-A650-4824-80B4-78DD1E11B3C5Q37117605-992BE258-86E6-475C-82A3-DC36462F7B9CQ37590908-770902B5-B1C9-4227-8663-41104B878157Q37651121-5F7044D2-BA5B-4463-A3E6-9768FBA7D075Q37667322-92C3B100-AB68-4F99-AD14-7164F2EF8A0AQ38093766-28BBAE2F-7EC8-4AD8-A5E0-1E6F8D38BC78Q38120527-C0F4CCC4-1264-4DB2-A74A-9F294AA3DE19Q38130445-40745F75-57C1-451C-A446-3E5D4A4F442FQ38388778-0DA38681-AF60-4444-B795-604C2BE57C91Q38991227-D3F70AAC-ADE0-4948-944E-CEE7BCAFDD98Q39973284-16CDA6E3-D241-407E-B2FE-2F1BA7D27363Q41546370-101273CC-87E1-493C-8EAD-992DD63EE960Q44601099-7CB14C2F-5163-48DA-B007-0A8E75EB50E5Q45071794-80187039-66BC-446F-A36B-F5038E95EDF6Q46425910-85080308-FD91-4785-9ECB-D924085645E2Q47225588-1D177CDD-DA05-4265-8886-0F4426BCEEE1Q47901567-FAD45A68-E362-44BD-A6A3-64FE3887CEB8Q47978062-A4331A99-275F-45EC-BB5E-1B28168962AEQ48125672-A0655A9E-0BCE-46E7-BEEC-1BD5EAA25CE5Q49918369-C01AD43A-09A1-412C-B58E-50BCE63F8D95Q50852822-D9420192-BD5F-406C-B2E3-7E04D47C8023Q50901331-FDA0ECC2-50B6-4D67-9EAD-7C8A4405BC14Q54351297-6CE90E66-37F1-44C1-9BF9-4BA7D5DA89F5Q54563660-463519E1-E889-49EC-A72A-53B8FF90386BQ55450138-F7DE0BE3-77D6-4EE8-81EB-468E13639216Q57298108-B4274948-05DC-405D-A4AC-4A5EC53A9E77Q57817463-5539E012-14D5-4EE3-A304-8FFB1CDCCF90Q58555322-F375A408-083E-42AA-979D-F1771E84B0B3
P2860
description
2011 nî lūn-bûn
@nan
2011 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年学术文章
@wuu
2011年学术文章
@zh-cn
2011年学术文章
@zh-hans
2011年学术文章
@zh-my
2011年学术文章
@zh-sg
2011年學術文章
@yue
name
Multiple sclerosis: pathogenesis and treatment.
@ast
Multiple sclerosis: pathogenesis and treatment.
@en
type
label
Multiple sclerosis: pathogenesis and treatment.
@ast
Multiple sclerosis: pathogenesis and treatment.
@en
prefLabel
Multiple sclerosis: pathogenesis and treatment.
@ast
Multiple sclerosis: pathogenesis and treatment.
@en
P2860
P1476
Multiple sclerosis: pathogenesis and treatment.
@en
P2093
Ingrid Loma
Rock Heyman
P2860
P304
P356
10.2174/157015911796557911
P577
2011-09-01T00:00:00Z